EDISON

QuickView

Genedrive

Point-of-care diagnostics driving rapid care decisions

Genedrive commercialises rapid pharmacogenetic diagnostic tests for use in acute healthcare settings. The company's two leading products are marketed to address unmet clinical needs, with its MT-RNR1 buccal test designed to prevent antibiotic induced hearing loss in neonates and its CYP2C19 product identifying stroke and cardiovascular patients unlikely to respond to clopidogrel (a commonly used antiplatelet medication). Commercial efforts are targeting the UK market (and broad National Health Service coverage) while expansion efforts to Europe and the Middle East are underway, as well as external studies to support a US FDA 510(k) filing application for CYP2C19.

Rapid genetic testing for time-critical situations

Genedrive's platform is designed to detect areas where individual genetic variations can affect how people respond to specific drugs (pharmacogenomics, or PGx), whereby an established drug can be ineffective and/or even harmful for individuals carrying specific genetic traits. While most PGx tests require central labs for analysis, which can take days to weeks to generate data, Genedrive's tests can deliver results often in less than an hour in a point-of-care (PoC) setting. This enables actionable treatment decisions in time-critical emergency situations. The CYP2C19 test is designed to guide appropriate antiplatelet therapy once a patient experiences a stroke, where recurrence risk is high for c 48 hours.

UK clinical guidelines could boost MT-RNR1 adoption

MT-RNR1 adoption should benefit from recently published UK clinical guidelines, which recommend testing for this genotype prior to aminoglycoside drug administration (as c 0.2% of the population can be susceptible to drug-induced hearing damage) and name Genedrive's MT-RNR1 kit, the only PoC test for this biomarker available for routine use in UK neonatal intensive care units. Analysis from the real world PALOH-UK study, expected in October, could reinforce clinical guidance and strengthen potential for long-term NHS coverage.

Undemanding EV valuation of c £20m

Preliminary FY26 trading results shows increasing traction, with £1.4m in sales, up c 45% y-o-y. Given widespread use of aminoglycosides among neonates and the high incidence of stroke (100k/year in the UK alone), Genedrive estimates the annual market opportunity for the two rapid testing products at c £26m in the UK and more than c £450m worldwide. Successful execution towards gaining market share could provoke a re-rating, although partnerships may be needed as each targeted country may require market access and reimbursement mapping, distributor and key opinion leader engagement and pilot-stage implementations prior to wide adoption.

Historical financials

Year end	Total revenues (£m)	EBITDA (adj) (£m)	PBT (£m)	EPS (p)	P/E (x)	EV/Adj EBITDA (x)
6/24	0.5	(5.1)	(7.8)	(4.70)	N/A	N/A
6/25	1.0	(5.3)	(5.4)	(0.90)	N/A	N/A

Source:Genedrive

Healthcare

28 August 2026

Price	**1.33p**
Market cap	**£21m**

Share price performance



Share details

Code	GDR
Listing	AIM
Shares in issue	1,605.6m
Net cash/(debt) at 30 June	£3.0m

Business description

Genedrive is a pharmacogenetic testing company focused on developing and commercialising low-cost, rapid point-of-care tests to enable precision-based medicine and optimise patient outcomes, particularly in time-critical emergency settings.

Bull points

- Recent UK clinical guidelines support use of MT-RNR1 testing in infants.
- CYP2C19 collaboration with Thermo Fisher Scientific to develop test using real-time PCR platform provides external validation.
- Recruitment recently completed for real-world PALOH-UK study (c 6,000 infants), which could boost NICE's conditional MT-RNR1 guidance towards a full recommendation.

Bear points

- Fund-raising likely required within the next 12 months given £0.5m monthly cost base.
- Maternal MT-RNR1 screening programmes and/or emergence of competitors could impede adoption
- Larger commercial scale and/or partnerships likely required to commercialise PoC diagnostics effectively in US and larger markets outside UK.

Analyst

Pooya Hemami, OD MBA, CFA +44 (0)20 3077 5700

healthcare@edisongroup.com

Edison profile page

EDISON QUICKVIEWS ARE NORMALLY ONE-OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

General disclaimer and copyright

This report has been prepared and issued by Edison. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or sol icitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London | New York | Frankfurt
20 Red Lion Street
London, WC1R 4PS
United Kingdom